Why Merck’s Keytruda keeps expanding, the cancer drug that will not sit still

Reviewed: ad hoc news B2B & Pro desk. Edited and checked on 2026-06-20, 12:47. Details in the imprint.

With Keytruda, Merck & Co. sends an oncology drug into everyday hospital life that has changed how many tumors are treated. On ward rounds, the name pops up on infusion bags, tumor boards, and discharge letters. It is present, quiet, and incredibly consequential.

What Keytruda actually is

Keytruda is a humanized monoclonal antibody that targets the PD-1 checkpoint on T cells, lifting a natural brake in the immune system so it can attack cancer cells more effectively.

The drug is given as an intravenous infusion, usually every three or six weeks depending on the dosing schedule and tumor setting. On infusion chairs, that means a transparent bag, a line, and often a long conversation between patients and nurses.

Where the drug is already standard

Keytruda has one of the broadest oncology labels on the market, covering malignancies such as non-small cell lung cancer, melanoma, head and neck cancer, classical Hodgkin lymphoma, and various gastrointestinal tumors.

Regulators in the United States and Europe have approved Keytruda in dozens of settings, often in combination with chemotherapy or targeted drugs and increasingly in earlier disease stages where cure is the goal rather than just life extension.

The feeling in real-world use

For oncologists, prescribing Keytruda has become almost routine in some tumor types, even though it is still a high-end therapy. Treatment discussions now regularly include whether a patient is a candidate for anti-PD-1 therapy and how long to continue it.

Patients often experience the therapy as less acutely aggressive than classic chemotherapy, because Keytruda is not associated with hair loss or immediate nausea in most cases. Instead, they are warned about subtler, sometimes delayed immune-related side effects.

Benefits that made the reputation

Keytruda gained its reputation because it can produce durable responses in some patients, with tumors shrinking and staying under control for years even after therapy stops in selected cases.

In metastatic melanoma and certain lung cancer populations, the drug has significantly improved overall survival compared with previous standard therapies, turning some previously grim diagnoses into chronic, manageable diseases for a subset of patients.

Where the limits show

Despite the success stories, Keytruda does not work for everyone. Many tumors remain insensitive or develop resistance after an initial response, leaving doctors and patients searching for the next option.

Side effects can also be serious: because the immune system is being pushed, it can attack healthy organs and cause inflammation in the lung, liver, bowel, skin, or endocrine glands, sometimes requiring high-dose steroids or even discontinuation of therapy.

Position against competitors

Keytruda competes mainly with other checkpoint inhibitors such as Bristol Myers Squibb’s Opdivo and, in some indications, with more recently approved PD-1 or PD-L1 antibodies from other manufacturers.

However, the breadth of the Keytruda label and the volume of clinical data behind it give Merck a strong first-mover advantage in many tumor types, keeping the drug firmly anchored in treatment algorithms worldwide.

Pipeline and future combinations

Merck is aggressively testing Keytruda in combination with other immunotherapies, targeted agents, chemotherapy, and radiotherapy to deepen responses and broaden the patient population that benefits.

In practice, that could mean more complex regimens on the ward, with Keytruda becoming part of multi-drug cocktails tailored to the genetic and immunologic profile of each tumor.

How it reaches hospitals

Keytruda is supplied as vials with a concentrate solution that pharmacists dilute for infusion. Cold-chain logistics and strict handling rules are mandatory, so the drug typically runs through hospital pharmacies and specialized oncology centers.

In Europe and the United States, reimbursement structures differ, but Keytruda usually sits in the high-price segment of oncology therapies and is financed via hospital budgets, national health systems, or private insurers rather than directly by patients.

What matters for patients and doctors

In daily practice, the key questions are often pragmatic. Is the PD-L1 status high enough to justify monotherapy? Do comorbidities increase the risk of immune-related toxicities? Can the patient come to the clinic every few weeks for infusions?

These conversations determine whether Keytruda is chosen alone, in combination, or not at all. The drug has become a central part of shared decision-making in oncology consult rooms, influencing not only survival charts but also how patients plan their everyday life around treatment.

Context for Merck & Co. and its stock

Keytruda is now the commercial and strategic backbone of Merck & Co.’s oncology portfolio, funding a broad pipeline of follow-on immunotherapies and combination studies that the company presents regularly to investors and clinicians. Shares of Merck & Co. Inc. (US58933Y1055) trade on the New York Stock Exchange in US dollars.

This article was AI-assisted and editorially reviewed. Product information without guarantee; prices and availability may change at short notice. No investment advice, no buy or sell recommendation. Stock-market transactions involve risks up to total loss.

en | US58933Y1055 | MERCK & CO. | boerse | 69589537 | bgmi